Company intelligence / Profile preview

Qanatpharma

Stans, Nidwalden, Switzerlandqanatpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 1 bioequivalence study of lumacaftor; top-line results expected in mid/late 2024. Preparing for a Phase 2 proof-of-concept trial to test lumacaftor’s effect on cerebral blood flow autoregulation and cognitive decline in heart failure patients. Received Orphan Drug Designation from EMA and FDA for SAH indication using CFTR-correctors.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecules (notably CFTR-correctors such as lumacaftor)AI/machine-learning drug discovery approachesTranscriptomic/proteomic platforms
Industry: Biotech

Drug pipeline

1 asset

lumacaftor

Phase 2

Indications: Heart failure

Partnerships

University of Toronto research collaboration

Beyond the preview

Go deeper on Qanatpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qanatpharma.

Explore the full profile